Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.6 HKD | +1.59% | +0.20% | +22.49% |
04:47pm | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
03:01pm | Everest Medicines Commercially Launches Kidney Disease Drug in China | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.49% | 1.03B | - | ||
-2.47% | 89.37B | A- | ||
+2.76% | 40.65B | A- | ||
-13.42% | 32.81B | B- | ||
+52.41% | 25B | A | ||
-17.32% | 15.29B | C | ||
-42.45% | 11.61B | B | ||
-10.48% | 11.49B | D+ | ||
+6.14% | 8.98B | B+ | ||
-7.72% | 8.23B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1952 Stock
- Ratings Everest Medicines Limited